The stock of Charles River Laboratories International Inc (CRL) has gone down by -5.67% for the week, with a -9.15% drop in the past month and a -18.61% drop in the past quarter. The volatility ratio for the week is 3.69%, and the volatility levels for the past 30 days are 3.56% for CRL. The simple moving average for the past 20 days is -9.53% for CRL’s stock, with a -21.57% simple moving average for the past 200 days.
Is It Worth Investing in Charles River Laboratories International Inc (NYSE: CRL) Right Now?
Charles River Laboratories International Inc (NYSE: CRL) has a price-to-earnings ratio that is above its average at 581.99x. The stock has a 36-month beta value of 1.47. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 2 as “overweight,” 16 as “hold,” and 1 as “sell.”
The public float for CRL is 50.57M, and at present, short sellers hold a 6.53% of that float. On April 03, 2025, the average trading volume of CRL was 1.17M shares.
CRL) stock’s latest price update
The stock price of Charles River Laboratories International Inc (NYSE: CRL) has surged by 2.25 when compared to previous closing price of 145.99, but the company has seen a -5.67% decline in its stock price over the last five trading sessions. zacks.com reported 2025-03-31 that Charles River and Valo Health identify a potential therapeutic for lupus using their combined offering, Logica.
Analysts’ Opinion of CRL
Many brokerage firms have already submitted their reports for CRL stocks, with Goldman repeating the rating for CRL by listing it as a “Neutral.” The predicted price for CRL in the upcoming period, according to Goldman is $170 based on the research report published on March 21, 2025 of the current year 2025.
Citigroup, on the other hand, stated in their research note that they expect to see CRL reach a price target of $175, previously predicting the price at $155. The rating they have provided for CRL stocks is “Neutral” according to the report published on March 04th, 2025.
Redburn Atlantic gave a rating of “Neutral” to CRL, setting the target price at $188 in the report published on March 03rd of the current year.
CRL Trading at -8.88% from the 50-Day Moving Average
After a stumble in the market that brought CRL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.26% of loss for the given period.
Volatility was left at 3.56%, however, over the last 30 days, the volatility rate increased by 3.69%, as shares sank -10.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.09% lower at present.
During the last 5 trading sessions, CRL fell by -5.67%, which changed the moving average for the period of 200-days by -29.73% in comparison to the 20-day moving average, which settled at $165.00. In addition, Charles River Laboratories International Inc saw -19.13% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRL starting from FOSTER JAMES C, who purchase 6,075 shares at the price of $165.01 back on Feb 20 ’25. After this action, FOSTER JAMES C now owns 183,639 shares of Charles River Laboratories International Inc, valued at $1,002,436 using the latest closing price.
Girshick Birgit, the Corporate Executive VP & COO of Charles River Laboratories International Inc, purchase 1,514 shares at $164.63 during a trade that took place back on Feb 20 ’25, which means that Girshick Birgit is holding 55,058 shares at $249,250 based on the most recent closing price.
Stock Fundamentals for CRL
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.32 for the gross margin
The net margin for Charles River Laboratories International Inc stands at 0.0. The total capital return value is set at 0.04. Equity return is now at value 0.45, with 0.20 for asset returns.
Based on Charles River Laboratories International Inc (CRL), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at 0.27. The debt to equity ratio resting at 0.79. The interest coverage ratio of the stock is 2.08.
Currently, EBITDA for the company is 581.14 million with net debt to EBITDA at 4.35. When we switch over and look at the enterprise to sales, we see a ratio of 2.51. The receivables turnover for the company is 5.62for trailing twelve months and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.41.
Conclusion
To sum up, Charles River Laboratories International Inc (CRL) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
